ADVANTAGE, ITA to implement proprietary oncology decision-support platform

NewsGuard 100/100 Score

To improve outcomes and manage costs for members with cancer, ADVANTAGE Health Solutions, Inc.SM (ADVANTAGE) has contracted with ITA Partners (ITA) to implement eviti - ITA's proprietary oncology decision-support platform - across their provider network. ITA is an independent, third-party expert with nearly a decade of experience supporting oncology treatment decisions and patient care.

"Our mission is to provide managed care solutions to improve outcomes, keep costs low and improve the health and wellness of the communities we serve," said Dr. Anthony Akosa, VP medical affairs at ADVANTAGE. "eviti is on target with that mission and will ensure that our providers have access to all available evidence-based treatment options that meet current criteria, ultimately providing the best cost-effective cancer care for our members."

ADVANTAGE began its operations in 2000 and today is one of the fastest growing health plans in Indiana.

"eviti is a sophisticated, intelligent solution that delivers on the promise of managed care. We're confident it will help ADVANTAGE achieve their goals in the delivery of quality oncology care for their members," said Eduardo Beruff, chief executive officer and president of ITA Partners.

eviti is the first independent, fully-integrated solution that simultaneously addresses the quality and cost concerns of cancer patients, oncologists and insurance companies, in any treatment setting. Patients benefit from appropriate treatment for their cancer; while physicians are empowered with systematic access to the latest, most comprehensive, evidence-based treatment standards, as well as the benefit of streamlined reimbursement. Payers are assured that members are receiving cost-effective care within the scope of their plan benefits.

eviti was launched nationally in October 2010 to provide payer organizations and providers enhanced access to the best cancer treatment decision support available and to advance their performance in the delivery of quality care.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Advances and hurdles: The impact of AI on oncology care efficiency and mortality rates